Tomivosertib

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameTomivosertib
Drug Alias NameeFT-508
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMAP kinase-interacting serine/threonine-protein kinase 2 inhibitorsMAP kinase-interacting serine/threonine-protein kinase MNK1 inhibitors
TargetsMAP kinase-interacting serine/threonine-protein kinase 2MAP kinase-interacting serine/threonine-protein kinase MNK1
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell Lung +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEffector Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEffector Therapeutics IncNorthwestern University
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungBreast Neoplasms +[4] 
Inactive IndicationsProstatic Neoplasms, Castration-ResistantColorectal NeoplasmsTriple Negative Breast Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A